Cargando…
Pharmacologic Ascorbate in Myeloma Treatment: Doses Matter
Autores principales: | Violet, Pierre-Christian, Levine, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405158/ https://www.ncbi.nlm.nih.gov/pubmed/28292579 http://dx.doi.org/10.1016/j.ebiom.2017.03.014 |
Ejemplares similares
-
Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid
por: Xia, Jiliang, et al.
Publicado: (2017) -
Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients
por: Bolaman, Ali Zahit, et al.
Publicado: (2021) -
Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial
por: Coppock, Dagan, et al.
Publicado: (2022) -
High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study
por: Polireddy, Kishore, et al.
Publicado: (2017) -
Correction: Coppock et al. Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial. Life 2022, 12, 453
por: Coppock, Dagan, et al.
Publicado: (2022)